Coenzyme Q10

CAS Number	303-98-0 (verified against PubChem CID 5281915)
Molecular Formula / MW	C59H90O4 / 863.34 g/mol
Chemical Class	Benzoquinone with a 10-unit isoprenoid side chain — hence "Q10". Extremely lipophilic
Redox Forms	Ubiquinone (oxidized) ↓↑ Ubiquinol (reduced) — interconvert in vivo
Source	Endogenously synthesised in all cells; commercial material by yeast fermentation
Typical Standardisation	CoQ10 by HPLC, ≥98%. Bioavailability is formulation-dependent, not purity-dependent
Claim Strength (Overview)	Moderate for chronic heart failure (Q-SYMBIO and meta-analyses); Emerging for statin-associated muscle symptoms
Buy from Herbuno	Coenzyme Q10 Pure Powder →

Name origin: Coenzyme Q10 is named for its function (a coenzyme), its quinone head group (Q), and the ten isoprenoid units in its tail (10). The alternative names ubiquinone and ubidecarenone reflect its ubiquity — it is found in essentially every cell membrane in every aerobic organism. The long isoprenoid tail makes it extraordinarily lipophilic, which is the root of every bioavailability problem this ingredient has. Traditional use: None applies, and none should be invented. CoQ10 was isolated in 1957 and its role in the mitochondrial electron transport chain elucidated by Peter Mitchell, whose chemiosmotic theory won the 1978 Nobel Prize in Chemistry. Its therapeutic use is entirely a product of modern biochemistry. Research trajectory: CoQ10 research has been unusually focused on cardiovascular endpoints, and for a coherent reason: cardiac muscle has the highest CoQ10 concentration of any tissue, myocardial CoQ10 levels are depressed in heart failure, and the degree of depletion correlates with severity. This produced Q-SYMBIO, a randomized double-blind trial with hard clinical endpoints rather than surrogate markers — a rarity in the supplement literature. Commercial source: Yeast-fermented CoQ10, supplied as ubiquinone (the oxidized form). Note that formulation, not purity, governs absorption.

---

Evidence for Coenzyme Q10 Applications

The Q-SYMBIO trial is the most substantial evidence in this monograph and deserves precise reporting. In a randomized, double-blind, multinational trial, patients with moderate to severe chronic heart failure received CoQ10 at 300 mg daily or placebo in addition to standard therapy; the European sub-population analysis confirmed the main finding, reporting significant improvement in all-cause mortality, cardiovascular mortality, NYHA classification, and left ventricular ejection fraction, and describing the therapeutic efficacy as safely reducing major adverse cardiovascular events, mortality, and hospitalisation (Mortensen 2019). Mortality is a hard endpoint. Very few supplements have moved one. Claim strength: Moderate.

The pooled evidence supports the direction of effect. A meta-analysis of randomized controlled trials in heart failure including 33 studies found all-cause mortality reduced (RR 0.64, 95% CI 0.48–0.85, p=0.002; GRADE moderate quality) and hospitalisation for heart failure reduced (RR 0.50, 95% CI 0.37–0.67, p<0.00001; GRADE moderate quality), with the incidence of adverse events not significantly different from control (Zhao 2024). Note the GRADE rating — moderate, not high — and note that this is adjunctive to standard therapy. Current AHA/ACC heart failure guidelines do not recommend initiating nutritional supplementation for heart failure treatment, and CoQ10 is not guideline-based therapy. Formulators must not present it as one. Claim strength: Moderate.

The statin question is the commercially dominant one and the evidence is genuinely mixed — a fact usually suppressed in marketing copy. Statins inhibit HMG-CoA reductase, which sits upstream of both cholesterol and CoQ10 synthesis in the mevalonate pathway, so statin-induced CoQ10 depletion is a mechanistically real and well-documented phenomenon. Whether supplementing CoQ10 relieves statin-associated muscle symptoms is a separate question, and here trials disagree: some meta-analyses report significant decreases in muscle pain, weakness, cramps and tiredness versus placebo; others find no benefit. Presenting this as settled would be dishonest. Claim strength: Emerging.

Bioavailability is the central practical problem and the one formulators most often get wrong. CoQ10 is a large (863 Da), extremely lipophilic, crystalline molecule with very poor aqueous solubility and erratic absorption. Purity is not the relevant variable — a 99% pure crystalline CoQ10 powder taken without lipid may be very poorly absorbed. What matters is formulation: solubilised, lipid-based, or crystal-dispersed delivery systems, and co-administration with dietary fat. A nominal milligram figure on a label tells a buyer little without knowing the delivery system. Claim strength: High (established pharmacokinetics).

The ubiquinone versus ubiquinol debate deserves a sceptical hearing rather than acceptance. Ubiquinol is the reduced form and is marketed as inherently superior in absorption; but the two forms interconvert readily in vivo, ingested ubiquinone is substantially reduced to ubiquinol during absorption, and comparative head-to-head bioavailability data is less decisive than the marketing suggests. Ubiquinol is also markedly less stable, oxidising readily on exposure to air, which creates real formulation and shelf-life burdens. Buyers should demand comparative pharmacokinetic evidence rather than paying a premium on assertion. Claim strength: Emerging (contested).

---

Dosage & Formulator Specification

Herbuno carries Coenzyme Q10 pure powder (ubiquinone). Formulators should understand that crystalline CoQ10 powder requires a delivery strategy — lipid co-formulation, solubilisation, or dispersion — to achieve meaningful absorption, and that purity of the raw material is not a substitute for one.

Clinical dosing in the heart failure literature has centred on 300 mg/day, the dose used in Q-SYMBIO, typically in divided doses; trials in other indications have commonly used 100–200 mg/day. Because CoQ10 is fat-soluble, absorption is substantially improved by taking it with a fat-containing meal — this is an actionable label instruction, not a nicety, and a formulator who omits it undermines their own product. Onset of effect in the cardiovascular trials was over months, not days.

Analytical verification should specify CoQ10 by HPLC (≥98%) and identify the redox form (ubiquinone vs ubiquinol), the production route (yeast fermentation is standard for the natural all-trans isomer; synthetic routes can yield cis-isomers that are not the endogenous form), and — the number that actually predicts performance — the delivery system and, ideally, comparative bioavailability data. Request the cis/trans isomer ratio, since only all-trans CoQ10 is the physiological molecule. For ubiquinol material, oxidative stability data across shelf life is essential rather than optional.

CoQ10 is well tolerated, with the heart failure meta-analysis finding adverse event incidence not significantly different from control; mild gastrointestinal upset is the most common complaint. Two interactions warrant clear statement. CoQ10 is structurally similar to vitamin K and has been reported to reduce the anticoagulant effect of warfarin — concurrent use requires medical supervision and INR monitoring, and this is a genuine rather than theoretical concern. Because CoQ10 may lower blood pressure modestly, caution is appropriate alongside antihypertensive medication. And it bears repeating: CoQ10 is not guideline-recommended therapy for heart failure, and anyone with heart failure should be under medical care rather than self-treating.

---

Frequently Asked Questions — Coenzyme Q10

Does CoQ10 help heart failure?
The Q-SYMBIO trial found that 300 mg/day added to standard therapy significantly improved all-cause and cardiovascular mortality, NYHA class, and ejection fraction — and a 33-study meta-analysis found all-cause mortality reduced (RR 0.64). That is a hard endpoint, which few supplements have moved. But it is adjunctive, GRADE moderate, and CoQ10 is not guideline-recommended therapy.

Does CoQ10 fix statin muscle pain?
Genuinely unresolved, and marketing that says otherwise is overselling. Statin-induced CoQ10 depletion is mechanistically real — statins inhibit the mevalonate pathway upstream of both cholesterol and CoQ10. But whether supplementing relieves the muscle symptoms is a different question, and meta-analyses disagree. Some find significant benefit; others find none.

Is ubiquinol better than ubiquinone?
Demand data rather than accepting the claim. The two forms interconvert readily in vivo, and ingested ubiquinone is substantially reduced to ubiquinol during absorption. Ubiquinol is also markedly less stable, oxidising on air exposure. The head-to-head bioavailability evidence is less decisive than the price premium implies.

Does CoQ10 purity determine absorption?
No — and this is the most common formulation error. CoQ10 is a large, extremely lipophilic crystalline molecule with poor aqueous solubility. A 99% pure powder taken without lipid may be very poorly absorbed. Formulation and co-administration with dietary fat are what matter, not the purity figure on the certificate.

Related compounds: Alpha-Lipoic Acid, L-Glutathione, Policosanol, Phytosterols

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery